Vivo Opportunity Fund Holdings, L.P. and three affiliated entities filed Amendment No. 2 to a Schedule 13G with the SEC on November 16, 2026, disclosing their beneficial ownership of common stock in Bright Minds Biosciences Inc. as of September 30, 2026.
Key Highlights
- Four reporting persons: Vivo Opportunity Fund Holdings, L.P., Vivo Opportunity, LLC, Vivo Opportunity Cayman Fund, L.P., and Vivo Opportunity Cayman, LLC each filed ownership disclosures for Bright Minds Biosciences Inc. common stock.
- Delaware entities hold 378,484 shares: Vivo Opportunity Fund Holdings, L.P. and its general partner Vivo Opportunity, LLC each report sole voting and dispositive power over 378,484 shares, representing 3.8% of the class.
- Cayman entities hold 39,395 shares: Vivo Opportunity Cayman Fund, L.P. and its general partner Vivo Opportunity Cayman, LLC each report sole voting and dispositive power over 39,395 shares, representing 0.4% of the class.
- No shared voting or dispositive power: All four reporting persons report zero shared voting power and zero shared dispositive power.
- Share count basis: The percentage figures are based on 9,864,061 shares of common stock outstanding as of June 30, 2026, as reported in the issuer's Current Report filed with the SEC on August 17, 2026.
- 5% or less ownership confirmed: The filing states ownership of 5 percent or less of the class under Item 5.
Vivo Opportunity's Position in Bright Minds Biosciences
According to the filing, Bright Minds Biosciences Inc. (NASDAQ:DRUG), a biosciences company headquartered at 400 N Aberdeen St Suite 900, Chicago, IL 60642, is the issuer of the common stock, no par value, covered by this disclosure. The triggering event for the amendment was September 30, 2026, and the filing was submitted on November 16, 2026 as Amendment No. 2 to a Schedule 13G.
The filing discloses two separate ownership structures within the Vivo group. Vivo Opportunity Fund Holdings, L.P., a Delaware limited partnership, holds 378,484 shares of record, with Vivo Opportunity, LLC serving as its general partner and therefore also reporting beneficial ownership of those same 378,484 shares. Separately, Vivo Opportunity Cayman Fund, L.P., a Cayman Islands limited partnership, holds 39,395 shares of record, with Vivo Opportunity Cayman, LLC, a Cayman Islands limited liability company, acting as its general partner and reporting the same 39,395 shares. All four entities report their holdings as representing 5 percent or less of the outstanding class. The filing states the entities are based at 192 Lytton Avenue, Palo Alto, CA 94301.
As required by Item 10 of the Schedule 13G, the reporting persons certified "that the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities." No shared power to vote or dispose of shares was reported by any of the four entities. Items 6, 7, 8, and 9 were each marked not applicable, indicating no ownership on behalf of another person, no subsidiary acquisition, no group membership, and no group dissolution to disclose.
What Was Disclosed
Four affiliated Vivo entities filed Amendment No. 2 to a Schedule 13G disclosing aggregate beneficial ownership of Bright Minds Biosciences Inc. common stock as of September 30, 2026, with the Delaware entities holding 378,484 shares at 3.8% and the Cayman entities holding 39,395 shares at 0.4%.




Please wait processing your request...